Smallpox and Monkeypox vaccine
| Vaccine description | |
|---|---|
| Target disease | Smallpox and Monkeypox |
| Type | live non-replicating |
| Clinical data | |
| Trade names | Jynneos |
| AHFS/Drugs.com | Professional Drug Facts |
| Routes of administration | Subcutaneous injection |
| ATC code | |
| Identifiers | |
| ChemSpider |
|
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}} |
The Smallpox and Monkeypox Vaccine sold under the trade name Jynneos [1] is a combination of two vaccines approved by the US FDA to prevent Smallpox and Monkeypox. It was approved in 2019. It is a live vaccine but cannot replicate. It is in the Strategic National Stockpile (SNS), It is approved for those with a high risk of either smallpox or monkeypox infection. It does not contain the viruses that cause smallpox or monkeypox. It is made from a vaccinia virus, a virus that is closely related to, but less harmful than either the variola or monkeypox viruses and can protect against both of these diseases. Jynneos contains a modified form of the vaccinia virus called Modified Vaccinia Ankara, which does not cause disease in humans and is non-replicating, meaning it cannot reproduce in human cells. This vaccine provides better protection against monkeypox than older smallpox vaccines.
References
- ↑ Commissioner, Office of the (24 March 2020). "FDA approves first live, non-replicating vaccine to prevent smallpox and monkeypox". FDA. Retrieved 21 May 2022.
References
This article "Smallpox and Monkeypox vaccine" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Smallpox and Monkeypox vaccine. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
